Create Account | Sign In: Author or Forum

News  |  Journals  |  Conferences  |  Opinion  |  Articles  |  Forums  |  Twitter    
Category: Family Medicine | Gastroenterology | Internal Medicine | Journal

Back to Journal Articles

Sorafenib May Improve Portal Hypertension

Last Updated: April 09, 2009.

Patients with advanced portal hypertension may benefit from sorafenib, researchers report in the April issue of Hepatology.


Significant treatment benefits seen in rats with models of portal hypertension and cirrhosis

Share |

Comments: (0)




THURSDAY, April 9 (HealthDay News) -- Patients with advanced portal hypertension may benefit from sorafenib, researchers report in the April issue of Hepatology.

Marc Mejias, of Hospital Clinic, Ciberehd in Barcelona, Spain, and colleagues studied the effects of sorafenib in two animal models: rats with pre-hepatic portal hypertension induced by partial portal vein ligation; and rats with intrahepatic portal hypertension and secondary biliary cirrhosis induced by bile duct ligation.

The researchers found that sorafenib was associated with an approximate 80 percent decrease in splanchnic neovascularization, an 18 percent decrease in portosystemic collateral vessels, and a 25 percent reduction in portal pressure. They also observed significant improvements in liver damage and intrahepatic fibrosis, inflammation and angiogenesis.

"As a whole, it is obvious that a new avenue for pharmacologic intervention in patients with cirrhosis has emerged," state the authors of an accompanying editorial. "The increasing knowledge of molecular biology has allowed the identification of new therapeutic targets to modulate cell biology, and this will affect the management of both malignant and non-malignant diseases. In the specific case of cirrhosis and liver cancer, it may be that the same agent or family of agents will be used for the prevention of fibrosis progression leading to cirrhosis, which at a point is the main risk factor for liver cancer development, and for the treatment of liver cancer itself, when this unfortunate development takes place."

An author of the editorial reports a financial relationship with the pharmaceutical industry, including Bayer.

Full Text

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Previous: Diverticular Perforation Up Sharply in United Kingdom Next: Minimum Threshold Suggested for HIV Antiretroviral Therapy

Reader comments on this article are listed below. Review our comments policy.

Submit your opinion:





Remember my personal information

Notify me of follow-up comments?


Useful Sites
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2017
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.